© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Ursula A. Matulonis, MD
Articles
Ursula A. Matulonis, MD, on KEYNOTE-100 Study Highlights for Patients
August 16, 2020
The expert from Dana-Farber Cancer Institute spoke about the study of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.
Ursula A. Matulonis, MD, on the KEYNOTE-100 Trial Final Results
August 08, 2020
The expert from the Dana-Farber Cancer Institute discussed the study findings which assessed the use of pembrolizumab monotherapy in patients with advanced recurrent ovarian cancer.
Ursula A. Matulonis, MD, on the KEYNOTE-100 Study Design
July 17, 2020
The expert from Dana-Farber Cancer Institute discussed the study design and inclusion criteria for this study of pembrolizumab in patients with advanced recurrent ovarian cancer.
Final Results from KEYNOTE-100 Show Promise for Pembrolizumab Monotherapy
June 20, 2020
The study results indicated that pembrolizumab monotherapy was associated with modest antitumor activity in patients with recurrent advanced ovarian cancer.